Soluble ACE2 and angiotensin II levels are modulated in hypertensive COVID-19 patients treated with different antihypertension drugs

References

• Attaway AH, Scheraga RG, Bhimraj A, et al. Severe covid-19 pneumonia: pathogenesis and clinical management. BMJ. 2021;372:n436.
   PubMedGoogle Scholar
• Guo J, Huang Z, Lin L, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of Angiotensin-Converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection. J Am Heart Assoc. 2020;9(7):e016219.
   PubMed Web of Science ®Google Scholar
• Tikellis C, Thomas MC. Angiotensin-Converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease. Int J Pept. 2012; (2012), :80.
   Google Scholar
• South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084–H1090.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li S, Niu S. ACE2 and COVID-19 and the resulting ARDS. Postgrad Med J. 2020;96(1137):403–407.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease Inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436(7047):112–116.
   PubMed Web of Science ®Google Scholar
• Medina-Enríquez MM, Lopez-León S, Carlos-Escalante JA, et al. ACE2: the molecular doorway to SARS-CoV-2. Cell Biosci. 2020;10(1):148.
   PubMed Web of Science ®Google Scholar
• Glowacka I, Bertram S, Herzog P, et al. Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63. J Virol. 2010;84(2):1198–1205.
   PubMed Web of Science ®Google Scholar
• Epelman S, Tang WHW, Chen SY, et al. Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-renin ratio and high soluble ACE2 system. J. Am. Coll. Cardiol. 2008;52(9):750–754.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Pfeffer MA. Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19. Eur Heart J. 2020;41(19):1818–1820.
   PubMed Web of Science ®Google Scholar
• Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097–1100.
   PubMed Web of Science ®Google Scholar
• Ciaglia E, Vecchione C, Puca AA. COVID-19 infection and circulating ACE2 levels: protective role in women and children. Front Pediatr. 2020;8:206–206.
   PubMed Web of Science ®Google Scholar
• Patel SK, Juno JA, Lee WS, et al. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur. Respir. J. 2021;57.
   Web of Science ®Google Scholar
• van Lier D, Kox M, Santos K, et al. Increased blood angiotensin converting enzyme 2 activity in critically ill COVID-19 patients. ERJ Open Res. 2021;7(1):00848–2020.
   PubMedGoogle Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610.
   PubMed Web of Science ®Google Scholar
• Karram T, Abbasi A, Keidar S, et al. Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure. Am J Physiol Heart Circ Physiol. 2005;289(4):H1351–8.
   PubMed Web of Science ®Google Scholar
• Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension. 2004;43(5):970–976.
   PubMed Web of Science ®Google Scholar
• Razeghian-Jahromi I, Zibaeenezhad MJ, Lu Z, et al. Angiotensin-converting enzyme 2: a double-edged sword in COVID-19 patients with an increased risk of heart failure. Heart Fail Rev. 2021;26(2):371–380.
   PubMed Web of Science ®Google Scholar
• Chouchana L, Beeker N, Garcelon N, et al. Association of antihypertensive agents with the risk of in-hospital death in patients with covid-19. Cardiovasc Drugs Ther. 2021.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Living guidance for clinical management of COVID-19. Available at https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-2.
   Google Scholar
• Lew RA, Warner FJ, Hanchapola I, et al. Angiotensin-converting enzyme 2 catalytic activity in human plasma is masked by an endogenous inhibitor. Exp Physiol. 2008;93(5):685–693.
   PubMed Web of Science ®Google Scholar
• Ramchand J, Patel SK, Srivastava PM, et al. Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease. PLOS One. 2018;13(6):e0198144.
   PubMed Web of Science ®Google Scholar
• Liu Y, Yang Y, Zhang C, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci. 2020;63(3):364–374.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11(8):875–879.
   PubMed Web of Science ®Google Scholar
• Huang F, Guo J, Zou Z, et al. Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun. 2014;5:3595.
   PubMed Web of Science ®Google Scholar
• Mortensen EM, Nakashima B, Cornell J, et al. Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes. Clin Infect Dis. 2012;55(11):1466–1473.
   PubMed Web of Science ®Google Scholar
• Reynolds HR, Adhikari S, Pulgarin C, et al. Renin-angiotensin-renin ratio and high soluble ACE2 system inhibitors and risk of covid-19. N Engl J Med. 2020;382(25):2441–2448.
   PubMed Web of Science ®Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9(1):757–760.
   PubMed Web of Science ®Google Scholar
• Sama IE, Ravera A, Santema BT, et al. Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-renin ratio and high soluble ACE2 inhibitors. Eur Heart J. 2020;41(19):1810–1817.
   PubMed Web of Science ®Google Scholar
• Mancia G, Rea F, Ludergnani M, et al. Renin-angiotensin-renin ratio and high soluble ACE2 system blockers and the risk of covid-19. N Engl J Med. 2020;382(25):2431–2440.
   PubMed Web of Science ®Google Scholar
• Yan F, Huang F, Xu J, et al. Antihypertensive drugs are associated with reduced fatal outcomes and improved clinical characteristics in elderly COVID-19 patients. Cell Discov. 2020;6(1):77.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers. Hypertension. 2020;75(6):1382–1385.
   PubMed Web of Science ®Google Scholar
• Wang C, Horby PW, Hayden FG, et al. A novel coronavirus outbreak of global health concern. Lancet. 2020;395(10223):470–473.
   PubMed Web of Science ®Google Scholar
• Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618–625.
   PubMed Web of Science ®Google Scholar
• Grobe JL, Mecca AP, Lingis M, et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am J Physiol Heart Circ Physiol. 2007;292(2):H736–42.
   PubMed Web of Science ®Google Scholar
• Nagy B, Jr,Fejes Z, Szentkereszty Z, et al. A dramatic rise in serum ACE2 activity in a critically ill COVID-19 patient. Int J Infect Dis. 2021;103:412–414.
   PubMed Web of Science ®Google Scholar
• Yeung ML, Teng JLL, Jia L, et al. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. Cell. 2021;184(8):2212–2228.e12.
   PubMed Web of Science ®Google Scholar
• Gerard L, Lecocq M, Bouzin C, et al. Increased angiotensin-converting enzyme 2 and loss of alveolar type II cells in COVID-19-related acute respiratory distress syndrome. Am J Respir Crit Care Med. 2021;204(9):1024–1034.
   PubMed Web of Science ®Google Scholar
• Chen Y, Huang D, Yuan W, et al. Lower serum angiotensin-converting enzyme level in relation to hyperinflammation and impaired antiviral immune response contributes to progression of COVID-19 infection. Infect Dis Ther. 2021;10(4):2431–2446.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Cai T, Fan L, et al. The potential role of serum angiotensin-converting enzyme in coronavirus disease 2019. BMC Infect Dis. 2020;20(1):883.
   PubMed Web of Science ®Google Scholar
• Yalcin HC, Sukumaran V, Al-Ruweidi MKAA, et al. Do changes in ACE-2 expression affect SARS-CoV-2 virulence and related complications: a closer look into membrane-bound and soluble forms. IJMS. 2021;22(13):6703–6703.
   Google Scholar
• Akin S, Schriek P, van Nieuwkoop C, et al. A low renin ratio and high soluble ACE2/renin ratio and high soluble ACE2 associate with COVID-19 severity. J. Hypertens. 2021;395(10229):1033–1034.
   Web of Science ®Google Scholar
• Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033–1034.
   PubMed Web of Science ®Google Scholar
• Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–402.
   PubMed Web of Science ®Google Scholar
• Biberoğlu S, İpekci A, İkizceli İ, et al. Role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19. Biomark Med. 2021;15(17):1581–1588.
   PubMed Web of Science ®Google Scholar
• Chappell MC, Pirro NT, South AM, et al. Concerns on the specificity of commercial ELISAs for the measurement of angiotensin (1-7) and Angiotensin II in human plasma. Hypertension. 2021;77(3):e29–e31.
   PubMed Web of Science ®Google Scholar
• Martins ALV, da Silva FA, Bolais-Ramos L, et al. Increased circulating levels of angiotensin-(1–7) in severely ill COVID-19 patients. ERJ Open Res. 2021;7(3):00114–2021.
   PubMedGoogle Scholar
• Heurich A, Hofmann-Winkler H, Gierer S, et al. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2014;88(2):1293–1307.
   PubMed Web of Science ®Google Scholar
• de Queiroz TM, Lakkappa N, Lazartigues E. ADAM17-Mediated shedding of inflammatory cytokines in hypertension. Front Pharmacol. 2020;11:1154.
   PubMed Web of Science ®Google Scholar
• Straus MR, Bidon M, Tang T, et al. FDA approved calcium channel blockers inhibit SARS-CoV-2 infectivity in epithelial lung cells, bioRxiv 2020.
   Google Scholar
• Tao X, Zhang L, Du L, et al. Allosteric inhibition of SARS-CoV-2 3CL protease by colloidal bismuth subcitrate. Chem Sci. 2021;12(42):14098–14102.
   PubMed Web of Science ®Google Scholar
• Wan Y, Shang J, Graham R, et al. Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus. J Virol. 2020;94:e00127–20.
   PubMed Web of Science ®Google Scholar
• Barbieri A, Robinson N, Palma G, et al. Can beta-2-Adrenergic pathway be a new target to combat SARS-CoV-2 hyperinflammatory syndrome?-lessons learned from cancer. Front Immunol. 2020;11:588724.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Narkiewicz K, Burnier M, et al. Potential protective effects of antihypertensive treatments during the covid-19 pandemic: from inhibitors of the renin-angiotensin system to beta-adrenergic receptor blockers. Blood Press. 2021;30(1):1–3.
   PubMed Web of Science ®Google Scholar
• Pinto-Sietsma S-J, Flossdorf M, Buchholz VR, et al. Antihypertensive drugs in COVID-19 infection. Eur Heart J Cardiovasc Pharmacother. 2020;6(6):415–416.
   PubMed Web of Science ®Google Scholar